Novavax Earns $125M from Sanofi Phase 3 Influenza Vaccine Trial
Novavax received a $125M milestone payment as Sanofi initiated a Phase 3, combination influenza-COVID-19 vaccine trial in Europe. Future collaboration milestones include an additional $300M upon U.S. launch.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed